{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:26:05Z","timestamp":1740108365772,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10096-019-03609-9","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T07:02:43Z","timestamp":1561014163000},"page":"1781-1785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early discharge criteria in patients with acute bacterial skin and skin structure infections in a large tertiary-care teaching hospital in Florence, Italy"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-6070","authenticated-orcid":false,"given":"Filippo","family":"Lagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Ottino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Mantengoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Distefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Corti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Farese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam","family":"Dannaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ipponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Falai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Maria","family":"Rossolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Bartalesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"3609_CR1","volume-title":"Guidance for industry acute bacterial skin and skin structure infections : developing drugs for treatment","author":"Food and Drug Administration","year":"2013","unstructured":"Food and Drug Administration. Guidance for industry acute bacterial skin and skin structure infections : developing drugs for treatment. 2013;"},{"key":"3609_CR2","doi-asserted-by":"crossref","unstructured":"Falcone M, Concia E, Giusti M, Mazzone A (2016) Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. Intern Emerg Med. 11(5):637-48","DOI":"10.1007\/s11739-016-1450-6"},{"key":"3609_CR3","doi-asserted-by":"crossref","unstructured":"Pollack CV, Amin A, Ford WT, Finley R, Kaye KS, Nguyen HH et al (2015) Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med 48(4):508-19","DOI":"10.1016\/j.jemermed.2014.12.001"},{"key":"3609_CR4","unstructured":"Esposito S, Bassetti M, Concia E, De Simone G, De Rosa FG, Grossi P et al (2017) Diagnosis and management of skin and soft-tissue infections ( SSTI ). A literature review and consensus statement : an update. J Chemother 29(4):197-214"},{"issue":"5","key":"3609_CR5","first-page":"143","volume":"4","author":"A Pulido-Cejudo","year":"2017","unstructured":"Pulido-Cejudo A, Guzm\u00e1n-Gutierrez M, Jalife-Monta\u00f1o A, Ortiz-Covarrubias A, Mart\u00ednez-Ordaz JL, Noyola-Villalobos HF et al (2017) Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis 4(5):143\u2013161","journal-title":"Ther Adv Infect Dis"},{"key":"3609_CR6","volume-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections : 2014 update by the Infectious Diseases Society of America","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections : 2014 update by the Infectious Diseases Society of America. 2014"},{"key":"3609_CR7","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/S1198-743X(16)30095-7","volume":"22","author":"A Russo","year":"2016","unstructured":"Russo A, Concia E, Cristini F, De RFG, Esposito S, Menichetti F et al (2016) Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect 22:S27\u2013S36","journal-title":"Clin Microbiol Infect"},{"key":"3609_CR8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QCO.0000000000000434","volume":"31","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Eckmann C, Peghin M, Carnelutti A, Righi E (2018) When to switch to an oral treatment and\/or to discharge a patient with skin and soft tissue infections. Curr Opin Infect Dis 31:163\u2013169","journal-title":"Curr Opin Infect Dis"},{"key":"3609_CR9","doi-asserted-by":"crossref","unstructured":"Nathwani D, Dryden M, Garau J, Hampshire R, Hospital C, Road R et al (2016) Early clinical assessment of response to treatment of skin and soft tissue infections. Int J Antimicrob Agents. 48(2):127-36","DOI":"10.1016\/j.ijantimicag.2016.04.023"},{"key":"3609_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijantimicag.2014.04.007","volume":"44","author":"C Eckmann","year":"2014","unstructured":"Eckmann C, Lawson W, Nathwani D, Solem CT, Stephens JM, Macahilig C et al (2014) Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents 44:56\u201364","journal-title":"Int J Antimicrob Agents"},{"key":"3609_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/0976-500X.130042","volume":"5","author":"J Cyriac","year":"2014","unstructured":"Cyriac J, James E (2014) Switch over from intravenous to oral therapy: a concise overview. J Pharmacol Pharmacother 5:83","journal-title":"J Pharmacol Pharmacother"},{"key":"3609_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.surge.2014.08.003","volume":"14","author":"N Chotai","year":"2016","unstructured":"Chotai N, Gallagher K, Kieffer WKM, Rogers BA, Ricketts DM (2016) A comparative analysis of the patient characteristics and cost of managing intravenous drug users (IVDU) with soft tissue abscesses with non-IVDU. Surgeon 14:13\u201317","journal-title":"Surgeon"},{"key":"3609_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0033-3182(94)71772-2","volume":"35","author":"SM Saravay","year":"1994","unstructured":"Saravay SM, Lavin M (1994) Psychiatric comorbidity and length of stay in the general Hospital: a critical review of outcome studies. Psychosomatics 35:233\u2013252","journal-title":"Psychosomatics"},{"key":"3609_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/23744235.2017.1365169","volume":"50","author":"T Nair","year":"2018","unstructured":"Nair T, Fitzgerald J, Ly B, Wallace MR (2018) Dalbavancin as a cost effective antibiotic. Infect Dis (Auckl) 50:75\u201376","journal-title":"Infect Dis (Auckl)"},{"key":"3609_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","volume":"24","author":"R Agarwal","year":"2018","unstructured":"Agarwal R, Bartsch SM, Kelly BJ, Prewitt M, Liu Y, Chen Y et al (2018) Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect 24:361\u2013368","journal-title":"Clin Microbiol Infect"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03609-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03609-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03609-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T16:02:18Z","timestamp":1575043338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03609-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3609"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03609-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Filippo Bartalesi, Giampaolo Corti, Bassam Dannaoui, Alberto Distefano, Tiziana Falai, Alessandra Ipponi, Filippo Lagi, Elisabetta Mantengoli, Letizia Ottino: the authors declare that they have no competing interests. Alessandro Bartoloni has received fees for presentation at local congress or expert meeting from Pfizer and MSD Italia. Alberto Farese has received fees for presentation at local congress or expert meeting from Becton-Dickinson and MSD Italia. Gian Maria Rossolini received grant and personal fees from Basilea, Merck, Nordic Pharma, Shionogi, Menarini; received personal fees from Pfizer and Qpex and non-financial support from Menarini; received fees for his hospital department from Venatorx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The local ethical committee (Comitato Etico Area Vasta Centro) approved the study with the reference number: 11689_oss.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}